Prevalence of type 2 diabetes mellitus in the pediatric population of a third-level care hospital in Mexico City in 2013 and 2018

doi:10.4239/wjd.v14.i3.290

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 3

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2751)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-2) series.

Item

Count

PDF

170

WORD

HTML

1549

Tables (1-2)

185

Sum=1936

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

229

Download

586

Sum=815

Mar 15, 2023 (publication date) through Nov 3, 2024

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Diabetes. Mar 15, 2023; 14(3): 290-298
Published online Mar 15, 2023. doi: 10.4239/wjd.v14.i3.290

Table 1 Clinical and biochemical characteristics of patients with type 2 diabetes

Variable	Patients with T2DM (2013)	Patients with T2DM (2018)	P value
Variable	n = 47	n = 104	P value
Sex [H (%)]	26 (55.3)	34 (32.7)	0.009
Age (yr)^a	12.96 ± 1.9	14.6 ± 1.9	0.000
Weight (kg)	62.6 ± 20.4	62.8 ± 19.4	0.956
Height (cm)	157.5 ± 14.2	156.9 ± 11.9	0.773
BMI (kg/m²)^a	25.3 ± 5.3	24.4 ± 6.7	0.170
Waist (cm)^a	84.7 ± 14.2	84.5 ± 19.2	0.905
Cholesterol total (mg/dL)	163.4 ± 33.1	172.5 ± 39.8	0.172
HDL-C (mg/dL)^a	40.7 ± 12.1	44.1 ± 8.6	0.087
LDL-C (mg/dL)^a	100.0 ± 25.3	95.9 ± 31.3	0.436
Triglycerides (mg/dL)^a	136.7 ± 92.0	147.7 ± 64.9	0.412
AST (U/L)^b	22.0 (11-143)	23.0 (11-89)	0.403
ALT (U/L)^b	43.0 (23-139)	36.0 (11-79)	0.005
Fasting glucose (mg/dL)^a	150.9 ± 88.1	189.0 ± 109.2	0.038
HbA1c (%)^a	10.5 ± 3.9	8.9 ± 2.8	0.069
Fasting insulin (mUI/mL)^b	11.2 (2-71)	11.2 (2-80)	0.902
C-peptide (ng/dL)^b	2.0 (0.09-8.0)	1.5 (0.1-8.5)	0.014
SBP (mmHg)^b	95.8 (70-130)	110 (90-150)	0.004
DBP (mmHg)^b	62.8 (48-85)	70.0 (60-90)	0.005
HOMA-β^b	135.9 (23-160.9)	50.2 (16-145)	0.183

^amean ± SD.

^bMedian (interquartile ranges).

T2DM: Type 2 diabetes mellitus; BMI: Body mass index; HDL-C: HDL cholesterol; LDL-C: LDL cholesterol; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; HbA1c: Hemoglobin A1c; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; HOMA-IR: Homeostatic Model of Assessment-Insulin Resistance.

Table 2 Family member and perinatal antecedents in the two study groups, n (%)

Variable	Patients with T2DM (2013)	Patients with T2DM (2018)	P value
Variable	n = 47	n = 104	P value
History of T2DM, in relatives of 1° and 2° [n (%)]	24 (51.1)	79 (75.9)	0.002
Antecedent of obesity in relatives of 1° and 2° [n (%)]	31 (65.9)	84 (80.7)	0.048
Antecedent of DM [n (%)]	7 (14.9)	9 (8.7)	0.249
Weight at birth (kg)	3.31 ± 0.66	3.03 ± 0.44	0.005
Socioeconomic status^a^,^b
Upper	5 (10.6)	6 (5.8)
Upper-middle	6 (12.8)	6 (5.8)
Middle	6 (12.8)	18 (17.3)	0.023
Lower-middle	16 (34)	18 (17.3)
Upper-Lower	10 (21.3)	28 (26.9)
Lower	4 (8.5)	28 (26.9)
Comorbidities
Hypercholesterolemia [n (%)]	22 (46.8)	29 (27.9)	0.023
Hypertriglyceridemia	27 (57.4)	78 (75.0)	0.030
Hypoalphalipoproteinemia	19 (40.4)	16 (15.4)	0.001
Hepatic steatosis	6 (12.8)	22 (21.2)	0.219
Arterial hypertension	5 (10.6)	22 (22.3)	0.021

^aAMAI/NSE 8 × 7 model.

^bPearson χ² test.

T2DM: Type 2 diabetes mellitus.

Citation: Molina-Díaz JM, Vargas-Terrez BE, Medina-Bravo PG, Martínez-Ambrosio A, Miranda-Lora AL, Klünder-Klünder M. Prevalence of type 2 diabetes mellitus in the pediatric population of a third-level care hospital in Mexico City in 2013 and 2018. World J Diabetes 2023; 14(3): 290-298
URL: https://www.wjgnet.com/1948-9358/full/v14/i3/290.htm
DOI: https://dx.doi.org/10.4239/wjd.v14.i3.290